Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New type of antiobiotic tackles hard-to-treat pediatric infections

28.10.2002


Pediatricians have another weapon in their arsenal to fight infections that have shown resistance to common antibiotics, according to data presented today by a team of investigators led by Baylor College of Medicine.



Study results showed that linezolid, a new type of antibiotic, is well-tolerated and as effective as the most common antibiotic, vancomycin, in treating infants and children with known or suspected gram-positive infections, reported Dr. Sheldon Kaplan, Baylor professor of pediatrics, to the Infectious Diseases Society of America meeting in Chicago. The results were presented in four posters.

"Incidence of these infections is increasing at an alarming rate in children in the community without typical risk factors, such as recent hospitalization," said Kaplan, also chief of the infectious disease service at Texas Children’s Hospital. "This underscores the need for new treatments for children with hard-to-treat resistant gram-positive infections, because there are limited options available for this age group."


The study included children with complicated skin and soft tissue infections, nosocomial pneumonia and bacteremia caused by resistant gram- positive bacteria including methicillin-resistant staphylococcus aureus (MRSA) and methicillin-resistant staphylococcus epidermidis. The multi-center study involved 52 sites nationwide, including Baylor/Texas Children’s. It enrolled 316 children from birth to age 11, including 63 neonates. The study was an open-label, randomized comparator-controlled trial comparing linezolid to vancomycin.

According to Kaplan, antibiotic-resistant infections are now more common in the general population.

"Most of the MRSA infections we see in children now come from the community, and it is becoming increasingly difficult to manage," he said. "Oral linezolid may become one of the most important options for treating community-acquired MRSA in the future." Linezolid is marketed as ZYVOX by Pharmacia Corporation.

Lori Williams | EurekAlert!
Further information:
http://research.bcm.tmc.edu/

More articles from Health and Medicine:

nachricht Another reason to exercise: Burning bone fat -- a key to better bone health
19.05.2017 | University of North Carolina Health Care

nachricht Disrupted fat breakdown in the brain makes mice dumb
19.05.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Wafer-thin Magnetic Materials Developed for Future Quantum Technologies

Two-dimensional magnetic structures are regarded as a promising material for new types of data storage, since the magnetic properties of individual molecular building blocks can be investigated and modified. For the first time, researchers have now produced a wafer-thin ferrimagnet, in which molecules with different magnetic centers arrange themselves on a gold surface to form a checkerboard pattern. Scientists at the Swiss Nanoscience Institute at the University of Basel and the Paul Scherrer Institute published their findings in the journal Nature Communications.

Ferrimagnets are composed of two centers which are magnetized at different strengths and point in opposing directions. Two-dimensional, quasi-flat ferrimagnets...

Im Focus: World's thinnest hologram paves path to new 3-D world

Nano-hologram paves way for integration of 3-D holography into everyday electronics

An Australian-Chinese research team has created the world's thinnest hologram, paving the way towards the integration of 3D holography into everyday...

Im Focus: Using graphene to create quantum bits

In the race to produce a quantum computer, a number of projects are seeking a way to create quantum bits -- or qubits -- that are stable, meaning they are not much affected by changes in their environment. This normally needs highly nonlinear non-dissipative elements capable of functioning at very low temperatures.

In pursuit of this goal, researchers at EPFL's Laboratory of Photonics and Quantum Measurements LPQM (STI/SB), have investigated a nonlinear graphene-based...

Im Focus: Bacteria harness the lotus effect to protect themselves

Biofilms: Researchers find the causes of water-repelling properties

Dental plaque and the viscous brown slime in drainpipes are two familiar examples of bacterial biofilms. Removing such bacterial depositions from surfaces is...

Im Focus: Hydrogen Bonds Directly Detected for the First Time

For the first time, scientists have succeeded in studying the strength of hydrogen bonds in a single molecule using an atomic force microscope. Researchers from the University of Basel’s Swiss Nanoscience Institute network have reported the results in the journal Science Advances.

Hydrogen is the most common element in the universe and is an integral part of almost all organic compounds. Molecules and sections of macromolecules are...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Dortmund MST Conference presents Individualized Healthcare Solutions with micro and nanotechnology

22.05.2017 | Event News

Innovation 4.0: Shaping a humane fourth industrial revolution

17.05.2017 | Event News

Media accreditation opens for historic year at European Health Forum Gastein

16.05.2017 | Event News

 
Latest News

New approach to revolutionize the production of molecular hydrogen

22.05.2017 | Materials Sciences

Scientists enlist engineered protein to battle the MERS virus

22.05.2017 | Life Sciences

Experts explain origins of topographic relief on Earth, Mars and Titan

22.05.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>